BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 7, 2026
Home » Keywords » GWAS

Items Tagged with 'GWAS'

ARTICLES

AI-generated illustration of DNA double helix

Deepmind’s AI model predicts the effect of variants in dark genome

Feb. 3, 2026
By Nuala Moran
No Comments
Google Deepmind is shedding light on the dark genome with its latest AI model, which is trained to decipher the 98% of DNA that does not code for proteins. Alphagenome is designed to predict how variants in the regulatory genome exert their effects on the expression of the genes they control.
Read More
AI-generated illustration of DNA double helix
Drug design, drug delivery & technologies

Deepmind’s AI model predicts the effect of variants in dark genome

Jan. 30, 2026
By Nuala Moran
No Comments
Google Deepmind is shedding light on the dark genome with its latest AI model, which is trained to decipher the 98% of DNA that does not code for proteins. Alphagenome is designed to predict how variants in the regulatory genome exert their effects on the expression of the genes they control.
Read More
AI-generated illustration of DNA double helix
Drug design, drug delivery & technologies

Deepmind’s AI model predicts the effect of variants in dark genome

Jan. 29, 2026
By Nuala Moran
No Comments
Google Deepmind is shedding light on the dark genome with its latest AI model, which is trained to decipher the 98% of DNA that does not code for proteins. Alphagenome is designed to predict how variants in the regulatory genome exert their effects on the expression of the genes they control.
Read More
Illustration of globe with DNA moving out of Africa
Cancer

African American ancestry study identifies lung cancer risk factors

Aug. 25, 2025
By Mar de Miguel
No Comments
Despite having lower smoking habits than other groups in the U.S., Black Americans are more likely to develop lung cancer, and their survival rates are significantly worse. What explains this disparity? Scientists at Vanderbilt University Medical Center have analyzed the genetics of their African ancestry in search of risk genes related to the disease and tobacco use. The results reveal new risk factors and confirm the presence of genetic variants that may contribute to the greater impact of lung cancer in this population.
Read More
Illustration of DNA, magnifying glass
Neurology/psychiatric

New target found in search for non-addictive pain drugs

Aug. 22, 2025
By Nuala Moran
No Comments
An investigation of the epidemiology and clinical characteristics of neuropathic pain in the UK Biobank has led to the discovery of a new pain gene and potential analgesic drug target in the peripheral nervous system. The gene, SLC45A4 (solute carrier 45A4), codes for a transporter that is involved in trafficking polyamines known to be involved in pain, across the cell membrane.
Read More
Illustration of DNA, magnifying glass

New target found in search for non-addictive pain drugs

Aug. 21, 2025
By Nuala Moran
No Comments
An investigation of the epidemiology and clinical characteristics of neuropathic pain in the UK Biobank has led to the discovery of a new pain gene and potential analgesic drug target in the peripheral nervous system. The gene, SLC45A4 (solute carrier 45A4), codes for a transporter that is involved in trafficking polyamines known to be involved in pain, across the cell membrane.
Read More
Liver illustration

Olix wins $630M deal from Eli Lilly for phase I MASH asset

Feb. 11, 2025
By Marian (YoonJee) Chu
Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock by 30% after it had largely recovered from a terminated deal with France’s Théa Open Innovation last year.
Read More
Liver illustration

Olix wins $630M deal from Eli Lilly for phase I MASH asset

Feb. 10, 2025
By Marian (YoonJee) Chu
Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock by 30% after it had largely recovered from a terminated deal with France’s Théa Open Innovation last year.
Read More
Female doctor with 3D medical model of pelvis
Genitourinary/sexual function

Neuregulin variant predicts gabapentin efficacy in chronic pelvic pain

July 31, 2024
Investigators at the University of Edinburgh have identified a genomic location linked to sensitivity to gabapentin in individuals with idiopathic chronic pelvic pain.
Read More
Biomarkers

Novel susceptibility loci revealed for systemic sclerosis

Feb. 2, 2024
Japanese researchers have presented data from the biggest Asian genome-wide association study (GWAS) regarding susceptibility loci for systemic sclerosis (SSc), comprising a total of 1,428 cases and 112,599 controls and with an imputation reference panel containing more than 3,000 Japanese whole-genome sequencing data.
Read More
More Articles Tagged with 'GWAS'

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 6, 2025.
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Brain illustrated with pills

    Serotonin receptor modulators for the treatment of OUD

    BioWorld Science
    Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
  • Liver anatomy illustration

    KLF15 shows potential as marker, target for cholangiocarcinoma

    BioWorld Science
    Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing